TXMD

BOCA RATON, Fla. (AP) — BOCA RATON, Fla. (AP) — TherapeuticsMD Inc. (TXMD) on Tuesday reported profit of $95,000 in its first quarter. The Boca Raton, Florida-based company said it had profit of 1 cent per share. The woman's health care product company posted revenue of $724,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TXMD at https://www.zacks.com/ap/TXMD

BOCA RATON, Fla., May 12, 2026--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2026. First Quarter 2026 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations totaled $103 thousand, compared to a net loss of $636 thousand for the first quarter of 2025. License Revenues from Continuing Operations The Company recorded $724 thousand in license revenue, primarily from the Mayne License Agreement, an increase of $331 thousand, compared to $393 thousand in license revenue for the first quarter of 2025. The increase is attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses were $1,447 thousand, a decrease of $227 thousand, or 13.6%, compared to $1,674 thousand for the first quarter of 2025. The decrease is primarily attributable to the absence of write-off expense recognized in 2025, as well as lower professional fees and share-based compensation costs. Evaluation of Strategic Alternatives The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet As of March 31, 2026, the Company’s cash and cash equivalents totaled $8.4 million. About TherapeuticsMD TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations. Forward...

BOCA RATON, Fla., March 30, 2026--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2025. Full Year 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(0.7) million, or $(0.06) per basic and diluted common share, an improvement of $1.7 million, compared to net loss from continuing operations of $(2.3) million, or $(0.20) per basic and diluted common share, for 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $3.0 million during the year ended December 31, 2025, an increase of $1.3 million, or 71.6%, compared to $1.8 million in license revenue during the year ended December 31, 2024. The increase is primarily attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses for 2025 were $7.4 million, a decrease of $0.5 million, or 5.9%, compared to $7.9 million for 2024. The decrease was primarily attributable to lower impairment charges recognized in 2025 compared to 2024, which were partially offset by higher bonus expense and increased costs related to investor communications. Evaluation of Strategic Alternatives The Company continues to evaluate a variety of strategic alternatives that may include, but are not limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not established a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet As of December 31, 2025, the Company’s cash and cash equivalents totaled $7.5 million. About TherapeuticsMD TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its b...

BOCA RATON, Fla., November 12, 2025--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended September 30, 2025. Third Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $50 thousand, or $0.00 per basic and diluted common share, compared to a net loss of $567 thousand, or $0.05 per basic and diluted common share, for the third quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $784 thousand for the third quarter of 2025, an increase of $237 thousand, compared to $547 thousand in license revenue for the third quarter of 2024. The increase is attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses for the third quarter of 2025 were $1,646 thousand, a decrease of $35 thousand, or 2.1%, compared to the third quarter of 2024, reflecting minimal change from the third quarter of 2024. Evaluation of Strategic Alternatives The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet As of September 30, 2025, the Company’s cash and cash equivalents totaled $7.1 million. About TherapeuticsMD TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and development or commercial operations. Fo...

BOCA RATON, Fla. (AP) — BOCA RATON, Fla. (AP) — TherapeuticsMD Inc. (TXMD) on Wednesday reported earnings of $152,000 in its third quarter. The Boca Raton, Florida-based company said it had profit of 1 cent per share. Earnings, adjusted to account for discontinued operations, were less than 1 cent on a per-share basis. The woman's health care product company posted revenue of $784,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TXMD at https://www.zacks.com/ap/TXMD

BOCA RATON, Fla., August 12, 2025--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Results Net Income (Loss) from Continuing Operations Net income from continuing operations was $545 thousand, or $0.05 per basic and diluted common share, compared to a net loss of $(1.05) million, or $(0.09) per basic and diluted common share, for the second quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.7 million, compared to $234 thousand in license revenue for the second quarter of 2024. The increase is primarily attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses for the second quarter of 2025 were $1,647 thousand, a decrease of $1,376 thousand, or 45.5%, compared to the second quarter of 2024. The change is primarily due to the impairment recognized in the second quarter of 2024. Evaluation of Strategic Alternatives The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet As of June 30, 2025, the Company’s cash and cash equivalents totaled $6.1 million. About TherapeuticsMD TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royalties from its licensees. The Company is no longer engaging in research and...

BOCA RATON, Fla. (AP) — BOCA RATON, Fla. (AP) — TherapeuticsMD Inc. (TXMD) on Tuesday reported net income of $551,000 in its second quarter. On a per-share basis, the Boca Raton, Florida-based company said it had net income of 5 cents. The woman's health care product company posted revenue of $952,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TXMD at https://www.zacks.com/ap/TXMD

BOCA RATON, Fla., May 13, 2025--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(636) thousand, or $(0.06) per basic and diluted common share, a decrease of $99 thousand, compared to net loss from continuing operations of $(809) thousand, or $(0.07) per basic and diluted common share, for the first quarter of 2024. License Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $393 thousand for the first quarter ended March 31, 2025, an increase of $80 thousand, or 25.8%, compared to $313 thousand in license revenue for the three months ended March 31, 2024. The increase is primarily attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses for the first quarter of 2025 were $1,264 thousand, a decrease of $191 thousand, or 13.1%, compared to the first quarter of 2024. The change is due to the increased efficiencies realized as a royalty-based business. Evaluation of Strategic Alternatives The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet As of March 31, 2025, the Company’s cash and cash equivalents totaled $5.7 million. About TherapeuticsMD TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a pharmaceutical royalty company, primarily collecting royaltie...

BOCA RATON, Fla. (AP) — BOCA RATON, Fla. (AP) — TherapeuticsMD Inc. (TXMD) on Tuesday reported a loss of $653,000 in its first quarter. The Boca Raton, Florida-based company said it had a loss of 6 cents per share. The woman's health care product company posted revenue of $393,000 in the period. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on TXMD at https://www.zacks.com/ap/TXMD

Net loss: US$2.31m (loss narrowed by 70% from FY 2023). US$0.20 loss per share (improved from US$0.74 loss in FY 2023). All figures shown in the chart above are for the trailing 12 month (TTM) period TherapeuticsMD shares are up 10% from a week ago. What about risks? Every company has them, and we've spotted 3 warning signs for TherapeuticsMD (of which 1 doesn't sit too well with us!) you should know about. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

BOCA RATON, Fla., March 27, 2025--(BUSINESS WIRE)--TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2024. Full Year 2024 Financial Results Net Loss from Continuing Operations Net loss from continuing operations was $(2.3) million, or $(0.20) per basic and diluted common share, a decrease of $5.4 million, compared to net loss from continuing operations of $(7.7) million, or ($0.74) per basic and diluted common share, for 2023. License and Service Revenues from Continuing Operations License revenue, primarily from the Mayne License Agreement, totaled $1.8 million during the year ended December 31, 2024, an increase of $0.5 million, or 35.3%, compared to $1.3 million in license revenue during the year ended December 31, 2023. The increase is primarily attributable to changes in sales of licensed products. Total Operating Expenses from Continuing Operations Total operating expenses for 2024 were $6.5 million, a decrease of $3.3 million, or 33.6%, compared to the $9.8 million for 2023. The decrease was due to the further optimization of the Company’s business through the reduction of costs and continued transition from a commercial business to a royalty-based business. Evaluation of Strategic Alternatives The Company continues to evaluate a variety of strategic alternatives that may include, but not be limited to, an acquisition, merger, other business combination, sale of assets, or other strategic transactions involving the Company. Although the Company is exploring potential strategic alternatives, there can be no assurance of a transaction, a successful outcome of these efforts, or the form or timing of any such outcome. The Company has not set a timetable for completion of this exploration process and does not intend to disclose further developments unless and until it is determined that disclosure is appropriate or necessary. Balance Sheet As of December 31, 2024, the Company’s cash and cash equivalents totaled $5.1 million. About TherapeuticsMD TherapeuticsMD was previously a women’s healthcare company with a mission of creating and commercializing innovative products to support the lifespan of women from pregnancy prevention through menopause. In December 2022, the Company changed its business to become a ph...